<DOC>
	<DOCNO>NCT00417261</DOCNO>
	<brief_summary>This first-in-human study design evaluate safety , tolerability , pharmacodynamic pharmacokinetic effect single multiple-doses ATF936 AXT914 administer orally healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Pharmacokinetic Effects Single Multiple-Doses ATF936 AXT914 Administered Orally Healthy Subjects .</brief_title>
	<detailed_description />
	<criteria>Study population : Openlabel safety cohort , Phases A B : Healthy male female subject age 18 68 year ( inclusive ) , good health determine past medical history , physical examination , vital sign assessment , electrocardiogram , routine laboratory testing ( hematology , biochemistry , urinalysis ) opinion investigator screen baseline . Female subject must nonchildbearing potential either surgically sterilize postmenopausal ( see inclusion criterion # 2 ) Phase C : Healthy postmenopausal female include 68 year age , good health determine past medical history , physical examination , vital sign assessment , electrocardiogram , routine laboratory testing ( hematology , biochemistry , urinalysis ) opinion investigator screen baseline . All Phases : Post menopausal status establish accord follow guideline : Cessation menses ≥ 3 year . Documented total hysterectomy/bilateral oophorectomy least 2 year prior study participation . Cessation menses &lt; 25 year . FSH level &gt; 30 IU/L ( confirm prior dose ) . All female subject , regardless age , must negative pregnancy test result screen baseline . At screen initial baseline , Vital sign supine position within follow range : Oral body temperature : 35.037.5 °C ( inclusive ) , Systolic blood pressure : 80 150 mm Hg ( inclusive ) , Diastolic blood pressure : 50 90 mm Hg ( inclusive ) , Pulse rate : 40 90 bpm ( inclusive ) Subjects must weigh least 60 kg participate study . Body Mass Index : Openlabel safety cohort , Phases A B : Subjects must body mass index ( BMI ) within range 18 28 kg/m2 , inclusive ( BMI 30 kg/m2 permissible demonstrated recruitment hinder upper limit 28 kg/m2 ) . Phase C : Subjects must body mass index ( BMI ) strictly within range 18 28 kg/m2 ( inclusive ) . Vitamin D 25 ( OH ) serum level ≥ 15 ng/ml ( subject Phase C Screening ) . All Phases : Normocalcemia serum calcium ≥ 8.5 mg/dL ≤ 10.2 mg/dL ( accord local lab range ) . All phase : Smokers ( use tobacco product previous 3 month ) . Smokers define report tobacco use and/or urine cotinine ≥ 300 ng/ml . Openlabel safety cohort , Phases A B : Use prescription nonprescription medication : Openlabel safety cohort , Phases A B : Use prescription drug within 4 week prior study start , and/or overthecounter ( OTC ) medication ( vitamin , herbal supplement , dietary supplement include ) within 2 week prior study start . If need , acetaminophen acceptable . Phase C : Use prescription and/or nonprescription drug ( include vitamin , herbal supplement , dietary supplement ) within 4 week prior study start , unless otherwise specify . If need , acetaminophen acceptable . Subjects use use within last 2 month , medicine one follow class ( Phase C ) : An HMG coA reductase inhibitor ( `` statin '' ) , thiazidetype diuretic , alpha adrenergic blocker , anticonvulsant ( example , diphenylhydantoin , phenobarbital carbamazepine ) heparin class anticoagulant . All Phases ( pertain primarily postmenopausal female ) : Subjects use used medicine one following class : Within last 3 month : Estrogens , Hormone replacement therapy include Selective Estrogens Receptor Modulators ( SERMs ) Within last 12 month : Strontium ranelate , PTH , Calcitonin , Aluminum supplement Within last 24 month : Bisphosphonates ( bisphosphonate use permit last 24 month ) Subjects history chronic use systemic corticosteroid ( oral i.v . ) within last year total dose exceeds 750 mg oral prednisone equivalent . [ NOTE : Use corticosteroid form topical cream , nasal inhaled formulation inject locally ( intraarticular ) one month prior screen NOT exclusionary ] . Subjects cancer history malignancy organ system , treat untreated , time , whether evidence local recurrence metastasis . [ NOTE follow exception apply : Basal cell squamous cell carcinoma skin colonic polyp noninvasive malignancy remove recur , carcinoma insitu ( CIS ) either breast , cervix uterus surgically remove recurred ] . History clinical evidence abnormal thyroid function thyroid disease ( hypoorhyperthyroidism , TBG deficiency , etc . ) endocrine disorder condition . Subjects bony deformity and/or neuromuscular irritability indicative chronic hypocalcaemia . Subjects history evidence previous/recent ( within 6 month ) fracture . Participation clinical investigation within 4 week prior initial dose longer require local regulation , limitation participation base local regulation . Donation loss 400 ml blood plasma within 8 week prior initial dosing , longer required local regulation . History clinical evidence bleed disorder ( i.e. , poor coagulation , prolong clotting time , etc . ) Screening and/or initial Baseline . Hemoglobin &lt; 12 g/dL Screening and/or initial Baseline . Significant illness within 2 week prior initial dosing . A past medical history clinically significant ECG abnormality family history ( grandparent , parent sibling ) prolong QTinterval syndrome . Any Surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study , include bowel , gastrointestinal , renal , pulmonary , pancreatic , hepatic , hematological , immunological , neurological disorder . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ATF936 , AXT914 , healthy subject , pharmacokinetics , parathyroid hormone , osteoporosis</keyword>
	<keyword>Healthy male female subject</keyword>
</DOC>